Today: 8 June 2026
Applied Materials stock jumps nearly 6% as Citi lifts target to $400, eyes turn to Feb. 12 earnings

Applied Materials stock jumps nearly 6% as Citi lifts target to $400, eyes turn to Feb. 12 earnings

New York, Feb 6, 2026, 12:35 EST — Regular session

  • Shares of Applied Materials climbed 5.7%, hitting $321.20 by midday trading
  • Citi raised its price target to $400 and maintained a Buy rating ahead of the Feb. 12 earnings report
  • Traders are focused on guidance regarding chip-factory investment and demand from China

Shares of Applied Materials jumped 5.7% to hit $321.20 on Friday, leading the charge among U.S. chip-equipment stocks in midday trading.

The surge comes as investors untangle the “picks-and-shovels” angle from the wider AI frenzy — a divide that’s grown messier this week amid Big Tech’s rising capex. “The market is no longer tolerating spending for spending’s sake,” said Mark Hawtin, head of global equities at Liontrust. Reuters

A new analyst note gave shares a boost. Citi’s Atif Malik bumped the price target on Applied Materials to $400 from $250, maintaining a Buy rating. He cited expectations for earnings to beat consensus thanks to upward revisions in spending from leading foundry and memory-chip firms.

Chip stocks spearheaded Wall Street’s bounce back following a tech-driven selloff earlier this week, according to a Reuters report. “The problem is we have to differentiate between potentially bad and certainly bad,” said Kristina Hooper, chief market strategist at Man Group. Reuters

Peers followed suit. Lam Research jumped 7.3%, KLA climbed 7.8%, and ASML was up 4.3% by midday.

Overnight, Reuters reported that Taiwan’s Winbond Electronics snapped up machinery from Applied Materials South EastAsia for T$7.45 billion, marking another sign of steady equipment orders fueled by memory demand.

Applied plans to release its fiscal first-quarter results on Feb. 12, with an earnings call scheduled for 4:30 p.m. ET that day.

Investors will be watching closely for any shift in the company’s outlook on wafer-fab equipment spending — the gear chipmakers use to build and upgrade fabs — and how that might impact the back half of the year, when the spending cycle can shift abruptly.

China remains a major concern. Applied Materials flagged that stricter U.S. export rules might limit its access to segments of the Chinese market, despite AI-driven memory demand bolstering some spending areas.

Tokyo Electron boosted its annual net profit forecast by 12.7% on Friday, signaling some stabilization in the equipment cycle in Asia. Yet in the U.S., investors remain wary, ready to sell off any signs of costly expansion that lacks immediate returns.

Applied Materials’ next key moment comes on Feb. 12, when it issues guidance. Investors will be watching closely to see if management hints at more stable customer demand through mid-2026 or warns of further uncertainty.

Stock Market Today

  • Zealand Pharma Shares Drop 20% After Trial Users Quit Weight-Loss Drug
    June 8, 2026, 4:55 AM EDT. Zealand Pharma's stock fell 20% in Copenhagen trading after the company reported that 20% of participants in a trial of its weight-loss drug stopped treatment due to gastrointestinal side effects. The high dropout rate raised concerns over the drug's tolerability, prompting investor caution. Zealand Pharma's announcement highlighted challenges in retaining patients during clinical trials, a key factor influencing the drug's market potential and future sales. The decline underscores the sensitivity of biotech stocks to trial outcomes and patient adherence issues.

Latest articles

Nokia drops after fast AI rally, traders stay focused

Nokia rally stalls as traders sell tech stocks after AI push

8 June 2026
Nokia shares plunged 2.98% in Helsinki to 12.690 euros, extending losses as investors dumped AI-linked tech stocks amid rising oil prices and rate fears; U.S. ADRs dropped 13.48% Friday, while no new operating update was given and Nokia issued 500 million euros in new debt, with the next key earnings test set for July 23.
SpaceX Sets IPO at $135, Retail Buzz Ahead of SPCX Nasdaq Debut

SpaceX Sets IPO at $135, Retail Buzz Ahead of SPCX Nasdaq Debut

8 June 2026
SpaceX’s $75 billion IPO launches June 12 at $135 a share, with retail demand already double the shares on offer and 30% of the deal earmarked for individuals, but 2025 losses of $4.94 billion and a $1.75 trillion target valuation raise questions about post-IPO pricing as index entry and profitability remain uncertain.
Eli Lilly Set for Key Monday After New Weight-Loss Drug Data

Eli Lilly Set for Key Monday After New Weight-Loss Drug Data

8 June 2026
Eli Lilly closed at $1,131.42, up 0.55%, after releasing late-stage data showing its obesity drug retatrutide led to 28.3% weight loss over 80 weeks and reduced sleep apnea and knee pain, fueling hopes its obesity pipeline could expand beyond weight loss as rivals Boehringer Ingelheim and Zealand Pharma unveiled competing data, setting up a key test for Lilly’s trillion-dollar valuation as trading resumes.
SK Hynix Slips Even After Nvidia Deal as Korean AI Shares Slide

SK Hynix Slips Even After Nvidia Deal as Korean AI Shares Slide

8 June 2026
SK Hynix plunged 7.68% to 1,911,000 won despite sealing a multi-year Nvidia memory deal, as fears of a U.S. rate hike and a tech stock rout triggered circuit breakers and an 8.3% KOSPI crash, overshadowing strong AI demand and ongoing HBM supply constraints.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 08.06.2026

8 June 2026
LIVEMarkets rolling coverageStarted: June 8, 2026, 4:00 AM EDTUpdated: June 8, 2026, 4:55 AM EDT Zealand Pharma Shares Drop 20% After Trial Users Quit Weight-Loss Drug June 8, 2026, 4:55 AM EDT.Zealand Pharma’s stock fell 20% in Copenhagen trading after the company reported that 20% of participants in a trial of its weight-loss drug stopped treatment due to gastrointestinal side effects. The high dropout rate raised concerns over the drug’s tolerability, prompting investor caution. Zealand Pharma’s announcement highlighted challenges in retaining patients during clinical trials, a key factor influencing the drug’s market potential and future sales. The decline underscores the
ARC Resources earnings jolt: Attachie guidance pulled as profit drops, reserves hit record
Previous Story

ARC Resources earnings jolt: Attachie guidance pulled as profit drops, reserves hit record

AbbVie stock rises as investors re-rank Rinvoq and Skyrizi after earnings jolt
Next Story

AbbVie stock rises as investors re-rank Rinvoq and Skyrizi after earnings jolt

Go toTop